When Will Constipation No Longer Be Idiopathic? A Review of Primary Constipation Pathogenesis, Diagnostics, and Emerging Treatments.
Thomas Melanie F MF, Driggers Kathryn E KE, McCarthy John G JG
Chronic primary constipation is common and burdensome yet is often labeled idiopathic despite growing evidence of physiologic heterogeneity. This invited, clinically oriented review examines emerging mechanisms underlying chronic constipation and their implications for phenotyping, diagnosis, and treatment. Microbial composition, methanogenesis, enteric serotonergic signaling, neuromuscular function, gut-brain interactions, and sex-related biological factors may contribute to distinct constipation phenotypes, although most associations lack validated biomarkers. Clinically, careful phenotyping remains essential, including exclusion of secondary causes, digital rectal examination, anorectal manometry with balloon expulsion testing, and, in a minority of patients, transit testing or defecography. Emerging diagnostic approaches, including artificial intelligence applied to anorectal testing and location-aware ingestible devices, may improve classification, but require prospective multicenter validation and demonstration of clinical benefit. Therapeutic options are also expanding: tenapanor is modestly effective for irritable bowel syndrome with constipation, vibrating capsules are authorized for chronic idiopathic constipation, and elobixibat provides proof of concept for ileal bile acid transport inhibition as a therapeutic target. Chronic primary constipation encompasses heterogeneous mechanisms that are incompletely captured by current diagnostics. Advances in physiologic phenotyping, novel diagnostic technologies, and mechanism-based therapies may enable more individualized management. Future progress will depend on phenotype-enriched trials that link reproducible mechanisms with actionable diagnostics and targeted therapy.